

Bladder & Bowel Institute, #1 global provider of InterStim® Therapy, announced its expansion into the Houston market.



The Woodlands, Texas Apr 22, 2026 ([IssueWire.com](https://www.issuewire.com)) - Bladder & Bowel Institute (BBI), a national leader in the treatment of bladder and bowel conditions, and the #1 global provider of InterStim® Therapy, today announced the acquisition of a new ambulatory surgery center in The Woodlands, Texas, marking its official expansion into the greater Houston market.

The expansion marks a significant step in improving access to care for underserved patients suffering from bladder and bowel conditions, many of whom go undiagnosed or untreated for years. The new facility, located in The Woodlands just north of Houston, is a 7,000-square-foot, state-licensed ambulatory surgery center with two operating rooms and one procedure room. The center is designed to support the growing demand for specialized bladder and bowel care across one of the largest and fastest-growing healthcare markets in the United States.

“This expansion reflects our commitment to bringing specialized care to patients who have historically been underserved,” said Jared Greer, CEO. “Houston is a key market for us, and this allows us to extend a proven care model to a broader patient population.”

BBI is widely recognized for its expertise in sacral nerve stimulation, including InterStim® Therapy, a minimally invasive treatment for bladder and bowel control conditions. The organization has performed more than 10,000 sacral nerve stimulation procedures and continues to expand access through its growing network of specialized centers.

“This is about more than entering a new market,” said Medical Director, Dr. Chris Taylor. “It is about delivering a consistent, high-quality treatment pathway to patients who need it, and building a program that drives strong outcomes from the start.”

Over the coming months, BBI will pursue accreditation from the Accreditation Association for Ambulatory Health Care (AAAHC) and work toward Medicare deemed status. The organization plans to begin the accreditation process in May with full operational launch targeted for August.

With existing locations in Dallas and Arkansas, BBI’s expansion into Houston extends its reach to a combined population of approximately 30 million people.

About Overactive Bladder

Overactive bladder (OAB) significantly impacts quality of life and can negatively affect social activities, exercise and cause disruptive nighttime voiding.^{1,2} Many sufferers are frustrated and embarrassed and limit their lives socially, professionally, and personally.³ However, 45% don't seek treatment and as many as seven in 10 stop using medications within six months due to intolerable side effects or unsatisfying results.^{4,5,6}

Evidence points to OAB being caused by a miscommunication between the bladder and brain.⁷ Sacral neuromodulation, or gentle stimulation of the sacral nerves, delivered by the InterStim® system is thought to normalize the brain-bladder communication pathway thereby restoring bladder function and alleviating symptoms. Restored function is defined as $\geq 50\%$ reduction in dysfunctional voiding symptoms from baseline. The InterStim® system is the only sacral neuromodulation solution proven to demonstrate sustained five-year efficacy and quality of life improvements for OAB.⁸

About Fecal Incontinence

Fecal incontinence (FI) is a distressing and disruptive chronic condition that is characterized by the inability to control bowel movements, which results in frequent accidents and leakage. People with FI report more depression and embarrassment, as well as lower quality of life compared to those without FI.⁹ Even though FI is treatable, 8.5 out of 10 adults haven't even told their doctor about their FI.¹⁰ The InterStim® system is the only sacral neuromodulation solution proven to demonstrate sustained five-year efficacy and quality of life improvements for FI.¹¹

About Medtronic® InterStim Therapy for Bladder and Bowel Control

Medtronic is the first and leading provider of neuromodulation solutions for bladder and bowel control issues. Sacral neuromodulation therapy delivered by the InterStim system was first approved twenty-five years ago and has helped more than 400,000 patients worldwide.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies –alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

- Coyne, K. S., C. Payne, et al.. "The impact of urinary urgency and frequency on health-related

- quality of life in overactive bladder: results from a national community survey." *Value Health* 2005;7(4): 455-463.
- Cartwright, R., S. Srikrishna, et al.. "Validity and reliability of patient selected goals as an outcome measure in overactive bladder." *Int Urogynecol J* 2011;22(7): 841-847.
 - Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. *Current Medical Research and Opinion*. 2007;23:65-76
 - Muller, N. "What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research." *Urol Nurs* 2005;25(2): 109-115.
 - Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. *Value in Health*. 2005;8(4)495-505.
 - Leede Research, "Views on OAB: A Study for the National Association of Continence." December 16, 2015.
 - Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. *Urol Clin N Am*. 2006;33:491-501.
 - Siegel, S., Noblett, K., Mangel J, et al. " Five Year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated with Sacral Neuromodulation." *J Urol*.2018;199(1), 229 – 236.
 - Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale - Quality of life instrument for patients with fecal incontinence. *Dis Colon Rectum*. 2000;43:9-16
 - Damon H, Guye O, Seigneurin A, et al. Prevalence of anal incontinence in adults and impact on quality-of-life. *Gastroenterol Clin Biol*. 2006;30(1):37-43.
 - Hull T, Giese C, Wexner SD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. *Dis Colon Rectum*. 2013;56(2):234-245.

Media Contact

Bladder & Bowel Institute

*****@bladderbowel.com

<https://bladderbowelinstitute.com/>

Source : Bladder & Bowel Institute

[See on IssueWire](#)